Original articlePositional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas
Introduction
Neuroblastoma is a biologically and clinically heterogenous disease. The clinical spectrum can range from spontaneous regression and maturation to aggressive dissemination despite multimodal therapy. Molecular genetics have been used to characterize and define clinically relevant subgroups of neuroblastoma [1], [2], [3], and several genetic alterations correlate with outcome and response to therapy (e.g., 1p loss, 17q gain, MYCN amplification, etc.) [4], [5], [6], [7]. Recent genome-wide analysis has identified novel regions of frequent allelic imbalance in neuroblastoma that may also be associated with distinct clinical subgroups [8]. In an effort to further define molecular subsets of neuroblastoma and to identify critically important genes, we performed genome-wide expression studies of human neuroblastic tumor samples. A subset of neuroblastomas was found to have high-level overexpression of genes at 12q13∼q15. The 12q region is altered in some tumors and is believed to harbor genes that may contribute to tumorigenesis. Amplification of 12q has been detected in sarcomas and gliomas, and several genes in this region are candidate oncogenes. In addition, allelic imbalance of 12q has been detected in human neuroblastoma and amplification has been reported in neuroblastoma cell lines [9], [10], [11], [12], [13], [14], [15], [16]. We further characterized the frequency of 12q gene overexpression and amplification in neuroblastomas and identified candidate oncogenes.
Section snippets
Patient tumor samples
A total of 129 samples were subjected to expression analysis, including 95 neuroblastomas, 12 ganglioneuromas, 12 cell lines, and 10 normal bone marrows.
Samples were snap-frozen immediately after surgical removal. Of the 95 neuroblastomas, 8 were stage 4S, 5 were stage 1, 13 were stage 2, 16 were stage 3, and 53 were stage 4 (International Neuroblastoma Staging System [INSS]). Histologic sections of the frozen tissue samples were reviewed and manually dissected to provide consistency and avoid
Contiguous genes at 12q are overexpressed in neuroblastoma
We performed a genome-wide expression analysis of 95 neuroblastomas using oligonucleotide arrays. Of the 95 neuroblastoma tumor samples, 5 demonstrated strong overexpression of contiguous genes at 12q13∼q15 (at least 2 standard deviations above the mean), and a focused analysis of gene expression in the region was carried out. All predicted genes at 12q13∼q15 currently listed in the human genome databases were identified (http://bioinformatics.weizmann.ac.il/cards/, //www.ncbi.nlm.nih.gov/LocusLink/
Discussion
The diverse clinical and molecular features of neuroblastomas have been widely investigated. At lease three disease patterns are recognized: (1) infants with widespread disease that can spontaneously regress without medical intervention (stage 4S); (2) local-regional disease that may recur but does not metastasize to the bone or bone marrow (stages 1–3); and (3) systemic disease with widespread metastasis that responds to cytotoxic therapy but frequently becomes resistant to medical treatment
References (42)
- et al.
The current contribution of molecular factors to risk estimation in neuroblastoma patients
Eur J Cancer
(1997) - et al.
Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?
Eur J Cancer
(1995) - et al.
Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers
Eur J Cancer
(1997) - et al.
Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line
Eur J Cancer
(1995) - et al.
A well-differentiated liposarcoma with a new type of chromosome 12-derived markers
Cancer Genet Cytogenet
(2001) - et al.
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents
Am J Pathol
(2001) - et al.
HuD, a neuronal-specific RNA-binding protein, is a potential regulator of MYCN expression in human neuroblastoma cells
Eur J Cancer
(1997) - et al.
Transcript mapping in a 46-kb sequenced region at the core of 12q13.3 amplification in human cancers
Genomics
(1997) - et al.
Cloning and expression of mitochondrial translational elongation factor Ts from bovine and human liver
J Biol Chem
(1995) - et al.
Experience with international neuroblastoma staging system and pathology classification
Br J Cancer
(2002)
Neuroblastoma. Effect of genetic factors on prognosis and treatment
Cancer
Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease
Cancer
Molecular genetics of neuroblastoma and the implications for clinical management: a review of the MSKCC experience
Oncologist
Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma
Cancer Res
Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma
Oncogene
Patterns of oncogene activation in human neuroblastoma cells
J Neurooncol
Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP
Cancer Genet Cytogenet
Molecular cytogenetic characterization and physical mapping of 12q13-q15 amplification in human cancers
Genes Chromosomes Cancer
Amplification at 12q13–14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site
Cancer Res
Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma
Genes Chromosomes Cancer
Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma
Cancer Res
Cited by (25)
Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses
2021, European Journal of CancerCitation Excerpt :Interestingly, MDM2 (12q15) and CDK4 (12q14.1) are located in close proximity to each other. Although rare, co-amplification of these genes has been reported as a recurrent event in neuroblastomas, with higher frequencies in relapse tumours [11–13]. Other aberrations that affect both pathways are those in CDKN2A, encoding both p14ARF (which blocks the binding of MDM2 to p53) and p16INK4a (which inhibits the CDK4-cyclin D1 complex).
The SLC26 gene family of anion transporters and channels
2013, Molecular Aspects of MedicineCitation Excerpt :However, Slc26a10 mRNA is abundantly expressed in heart (Alvarez et al., 2004) and has been evaluated as a biomarker of congestive heart failure (J.M. Hare, B. Heidecker, US Patent application 12/610,529; http://www.freepatentsonline.com/y2010/0112587.html). The SLC26A10 gene is predicted “with high confidence” to be under imprinting regulation (Luedi et al., 2007), and is within a transcribed 12q14–15 amplicon present in soft tissue sarcoma and atypical lipoma (Francis et al., 2007) (Trombetta et al., 2009) and in neuroblastoma and glioma (Lo et al., 2007; Su et al., 2004). SLC26A10 mRNA was downregulated 10-fold in gastric carcinoma cells by knockdown of PTP-1B (Wang et al., 2010a).
Identification of CDKN3 as a Key Gene that Regulates Neuroblastoma Cell Differentiation
2024, Journal of CancerGene Expression and Early Radiation Response of Two Distinct Neuroblastoma Cell Lines
2023, ONCOLOGY (United States)